We are live on ! Find out more
CPIX icon

Cumberland Pharmaceuticals

26 hedge funds and large institutions have $17M invested in Cumberland Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.43% more ownership

Funds ownership: 29.38%30.81% (+1.4%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

4% less funds holding

Funds holding: 2726 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

26% less capital invested

Capital invested by funds: $23M → $17M (-$5.99M)

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
5
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FGAM
26
Financial Gravity Asset Management
Texas
-$10K -2,000 Closed
Deutsche Bank
27
Deutsche Bank
Germany
-$5K -1,250 Closed
Bank of America
28
Bank of America
North Carolina
-$1K -154 Closed
Wells Fargo
29
Wells Fargo
California
+$228 +51 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
+$492 +110 New

CPIX Hedge Fund Activity: Q1 2020 in Review

26 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2020, worth a combined $17M — down 26% from $23M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CPIX and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.

The largest buyer was Berkshire Asset Management, opening a new position worth an estimated $736K. The largest seller was Bailard, exiting entirely with an estimated $61K sold.

  • 26 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2020, down from 27 in Q4 2019.
  • Funds reported $17M of Cumberland Pharmaceuticals stock for Q1 2020, down 26% quarter-over-quarter.
  • 5 funds opened new Cumberland Pharmaceuticals positions in Q1 2020 and 6 closed out, a net change of -1 holder.
  • The largest Cumberland Pharmaceuticals buyer in Q1 2020 was Berkshire Asset Management, an estimated $736K added.
  • The largest Cumberland Pharmaceuticals seller in Q1 2020 was Bailard, an estimated $61K sold.

Based on aggregated 13F filings for Q1 2020.